Substance-induced psychosis is a form of substance-related disorder where psychosis can be attributed to substance use. Various psychoactive substances have been implicated in causing or worsening psychosis in users.
Psychotic states may occur after using a variety of legal and illegal substances. Usually such states are temporary and not irreversible, with fluoroquinolone-induced psychosis being a notable exception. Drugs whose use, abuse, or withdrawal are implicated in psychosis include the following:
F10.5 alcohol: Alcohol is a common cause of psychotic disorders or episodes, which may occur through acute intoxication, chronic alcoholism, withdrawal, exacerbation of existing disorders, or acute idiosyncratic reactions. Research has shown that alcohol abuse causes an 8-fold increased risk of psychotic disorders in men and a 3 fold increased risk of psychotic disorders in women. While the vast majority of cases are acute and resolve fairly quickly upon treatment and/or abstinence, they can occasionally become chronic and persistent. Alcoholic psychosis is sometimes misdiagnosed as another mental illness such as schizophrenia.
F12.5 cannabinoid: Some studies indicate that cannabis, especially certain strains containing large proportions of THC and low proportions of CBD, may lower the threshold for psychosis, and thus help to trigger full-blown psychosis in some people. Recent studies have found an increase in risk for psychosis in cannabis users. It is not clear whether this is a causal link; it is possible that cannabis use only increases the risk of psychosis in people already predisposed to it.
The code F11.5 is reserved for opioid-induced psychosis, and F17.5 is reserved for tobacco-induced psychosis, but neither substance is traditionally associated with the induction of psychosis.
The code F15.5 also includes caffeine-induced psychosis, despite not being specifically listed in the DSM-IV. However, there is evidence that caffeine, in extreme acute doses or when severely abused for long periods of time, may induce psychosis.
JWH-018 and some other synthetic cannabinoids, or mixtures containing them (e.g. "Spice", "Kronic", "MNG" or "Mr. Nice Guy", "Relaxinol", etc.). Various "JWH-XXX" compounds in "Spice" or "Incense"  have also been found.
Mephedrone and related amphetamine-like drugs sold as "bath salts" or "plant food".
^Moore TH, Zammit S, Lingford-Hughes A, et al. (July 2007). "Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review". Lancet370 (9584): 319–28. doi:10.1016/S0140-6736(07)61162-3. PMID17662880.
^de Paola L, Mäder MJ, Germiniani FM, et al. (June 2004). "Bizarre behavior during intracarotid sodium amytal testing (Wada test): are they predictable?". Arquivos De Neuro-psiquiatria62 (2B): 444–8. doi:10.1590/S0004-282X2004000300012. PMID15273841.
^Sarrecchia C, Sordillo P, Conte G, Rocchi G (1998). "[Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication]". Annali Italiani Di Medicina Interna (in Italian) 13 (4): 237–9. PMID10349206.
^Brady, K. T.; R. B. Lydiard, R. Malcolm, and J. C. Ballenger (December 1991). "Cocaine-induced psychosis". Journal of Clinical Psychiatry52 (12): 509–512. PMID1752853.Cite uses deprecated parameters (help)
^Cerimele JM, Stern AP, Jutras-Aswad D (March 2010). "Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia". The American Journal of Psychiatry167 (3): 353. doi:10.1176/appi.ajp.2009.09101456. PMID20194494.
^Reeves RR (1992). "Ciprofloxacin-induced psychosis". Ann Pharmacother26 (7–8): 930–1. PMID1504404.
^Yasuda H, Yoshida A, Masuda Y, Fukayama M, Kita Y, Inamatsu T (March 1999). "[Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients]". Nippon Ronen Igakkai Zasshi (in Japanese) 36 (3): 213–7. doi:10.3143/geriatrics.36.213. PMID10388331.
^Marsepoil T, Petithory J, Faucher JM, Ho P, Viriot E, Benaiche F (1993). "[Encephalopathy and memory disorders during treatments with mefloquine]". Rev Med Interne (in French) 14 (8): 788–91. doi:10.1016/S0248-8663(05)81426-2. PMID8191092.
^Bergman, K. R.; Pearson, C.; Waltz, G. W.; Evans R. III (1980). "Atropine-induced psychosis. An unusual complication of therapy with inhaled atropine sulfate". Chest78 (6): 891–893. doi:10.1378/chest.78.6.891. PMID7449475.Cite uses deprecated parameters (help)
^Varghese, S.; Vettath, N.; Iyer, K.; Puliyel, J. M.; Puliyel, M. M. (1990). "Ocular atropine induced psychosis--is there a direct access route to the brain?". Journal of the Association of Physicians of India38 (6): 444–445. PMID2384469.Cite uses deprecated parameters (help)
^Barak, Segev; Weiner, I. (2006). "Scopolamine Induces Disruption of Latent Inhibition Which is Prevented by Antipsychotic Drugs and an Acetylcholinesterase Inhibitor". Neuropsychopharmacology32 (5): 989–999. doi:10.1038/sj.npp.1301208. PMID16971898.Cite uses deprecated parameters (help)
^Carey, R. J.; Pinheiro-Carrera, M.; Dai, H.; Tomaz, C.; Huston, J. P. (1995). "l-DOPA and psychosis: Evidence for l-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone". Biological Psychiatry38 (10): 669–676. doi:10.1016/0006-3223(94)00378-5. PMID8555378.